60 Degrees Pharmaceuticals, Inc. · NASDAQ:SXTP
60 Degrees Pharmaceuticals — 2026 ILADS Annual Scientific Conference
29 slides from 60 Degrees Pharmaceuticals's conference presentation, Oct 23, 2026
Slide 1: Tafenoquine for Babesiosis: Progress across acute, relapsing and chronic disease
Tafenoquine for Babesiosis Progress across acute, relapsing and chronic disease Geoffrey S. Dow, PhD Chief Executive Officer 2026 ILADS Annual Scientific Conference October 22–25, 2026 | Herndon, Virginia Reframing Complex Disease: Pathways to Treatment 2026 update A marketed antimalarial platform n
Slide 2: Disclaimer and Forward-Looking Statements
Disclaimer and Forward-Looking Statements DISCLAIMER. The information contained herein has been prepared to assist prospective investors in making their own evaluation of 60 Degrees Pharmaceuticals, Inc. (the "Company") and does not purport to be all-inclusive or to contain all of the information a
Slide 3: Disclaimer, Off-Label Use Statement & CME Goals
Disclaimer, Off-Label Use Statement & CME Goals Speaker disclosure I am an Officer, Director and Shareholder of 60 Degrees Pharmaceuticals, Inc. The Company has a commercial interest in tafenoquine for babesiosis. Perspective Opinions expressed are the speaker's own and do not necessarily reflect th
Slide 4: Ticks Transmit a Widening Set of Serious Diseases in the U.S.
Ticks Transmit a Widening Set of Serious Diseases in the U.S. Record tick-bite emergency room visits in 2026 underscore the rising need for targeted therapies. ER visits for tick bites RECORD LEVELS THIS YEAR (113,000+) One bite can transmit More bites + more clinical encounters multiple pathogens E
Slide 5: Phases and Development Stages
PHASES AND DEVELOPMENT STAGES PRODUCT NON-CLINICAL IND ENABLING PHASE 1 PHASE IIA PHASE IIB/III REGULATORY REVIEW COMMERCIALLY AVAILABLE COMMERCIALLY SUSTAINABLE ARAKODA® (tafenoquine): US MARKET ZAMVIO (tafenoquine): TICK-BORNE DISEASE – VETERINARY INDICATIONS Tafenoquine (ARAKODA regimen): TREATME
Slide 6: What Has Changed Since ILADS 2025?
P R O G R A M UP D A T E What Has Changed Since ILADS 2025? Five developments now shape the tafenoquine program. 30 Hospital subjects randomized Blinded follow-up completes in early January 2027; unblinding follows. 3 Expanded-access cures confirmed The first three patients were NAT- negative after
Slide 7: ARAKODA for Babesiosis: Clinical Development Map
O R I E N T A T IO N ARAKODA® for Babesiosis: Clinical Development Map Three clinical programs answer different questions — and feed one regulatory package. CHRONIC Who has active infection — and does clearance improve fatigue? SEVERE ACUTE Does tafenoquine accelerate sustained recovery? RELAPSING C
Slide 8: One Tafenoquine Backbone — Three Clinical Settings
R E G I M E N One Tafenoquine Backbone — Three Clinical Settings The sponsored studies use a four-day loading regimen followed by weekly dosing. LOADING 200 mg DAY 1 200 mg DAY 2 200 mg DAY 3 200 mg DAY 4 WEEKLY MAINTENANCE 200 mg 200 mg 200 mg 200 mg 200 mg 200 mg 200 mg Weekly until study-specific
Slide 9: Three-Day vs Four-Day Tafenoquine Loading Regimens
Three-Day vs Four-Day Tafenoquine Loading Regimens Illustrative plasma tafenoquine exposure with equal numbers of 200 mg doses 4-day load 3-day load Cmax 4-day loading produces a slightly earlier, modestly higher Cmax. ≈ Steady-state concentrations are similar after weekly dosing. MIC For the same n
Slide 10: ARAKODA: A Marketed Tafenoquine Safety Platform
SA F E T Y ARAKODA®: A Marketed Tafenoquine Safety Platform Safety evidence from malaria prophylaxis informs — but does not establish — use in babesiosis. FDA-approved malaria prophylaxis Adults 18 years and older • weekly maintenance dosing • marketed since 2019 2018 U.S. approval 2019 Commercial l
Slide 11: Weekly Tafenoquine Safety Was Comparable to Placebo
SA F E T Y Weekly Tafenoquine Safety Was Comparable to Placebo The main predictable difference was reversible cornea verticillata. 52-WEEK CONTROLLED STUDY 91.0% Any adverse event Tafenoquine 89.9% Any adverse event Placebo 6.3% Serious adverse event Tafenoquine 5.0% Serious adverse event Placebo Co
Slide 12: Safe Use Depends on Patient Selection and Monitoring
SA F E T Y Safe Use Depends on Patient Selection and Monitoring The long half-life makes pre-treatment screening especially important. SCREEN BEFORE DOSING G6PD status Contraindicated in G6PD deficiency or unknown G6PD status. Pregnancy / lactation Pregnancy testing is recommended; restrictions appl
Slide 13: Chronic Babesiosis: The Diagnostic-Development Bottleneck
C H R O N I C ST UD Y Chronic Babesiosis: The Diagnostic-Development Bottleneck The clinical question cannot be answered until exposure, active infection and species are separated. 1 EXPOSURE Serology, immunoblots suggest prior contact — but not necessarily viable organisms. 2 ACTIVE INFECTION A ver
Slide 14: B-FREE: Phase II Open-Label Study in Chronic Babesiosis
C H R O N I C ST UD Y B-FREE: Phase II Open-Label Study in Chronic Babesiosis A pragmatic design that screens broadly, but reserves the primary analysis for NAT-positive participants. NCT06656351 SCREEN Severe disabling fatigue ≥6 months + laboratory evidence of exposure within 12 months TREAT 200 m
Slide 15: Diagnostic Sensitivity Changes the Meaning of Negative
C H R O N I C ST UD Y Diagnostic Sensitivity Changes the Meaning of "Negative" Different assays answer different questions — and operate across five orders of magnitude. Approximate lower analytical sensitivity (parasites/mL; log scale) 10^5 10^4 10^3 10^2 10^1 10^0 Microscopy Microscopy ~100,000 pa
Slide 16: B-FREE Screening Update: A Genus Signal Without a Species Signal
C H R O N I C ST UD Y B-FREE Screening Update: A Genus Signal Without a Species Signal Early screening has not yet resolved whether symptoms reflect B. microti or an atypical Babesia. Patient Inclusion evidence Galaxy genus dPCR Red Cross B. microti NAT Mayo species-specific PCR A ≥1 IGENEX exposure
Slide 17: Response = no retreatment for at least weeks after treatment cessation; primary analysis retains
Response = no retreatment for at least 12 weeks after treatment cessation; primary analysis retains case 20 and excludes courses with unknown post-treatment follow-up. ©2026 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. 17
Slide 18: Why Pair Tafenoquine With Atovaquone?
R E L A P SI N G D I SE A SE Why Pair Tafenoquine With Atovaquone? Complementary oxidative mechanisms produced durable control in an immunodeficient mouse model. ATOVAQUONE Disrupts parasite mitochondrial electron transport and contributes to oxidative stress. + TAFENOQUINE Induces parasite oxidativ
Slide 19: First Published Tafenoquine Case Series in Relapsing Babesiosis
R E L A P SI N G D I SE A SE First Published Tafenoquine Case Series in Relapsing Babesiosis Krause et al. began to define the conditions for successful use in highly immunocompromised patients. Representative successful case Smear parasitemia, PCR status and treatment exposure over time 4 of 5 pati
Slide 20: Treatment order and duration by case
Each row preserves treatment order. Block width reflects duration on a logarithmic scale. 20
Slide 21: Published-Case Reanalysis: Duration Predicts Response
R E L A P S I N G D I S E A S E Published-Case Reanalysis: Duration Predicts Response A whole-episode Cox model tested whether longer uninterrupted treatment was followed by more durable response. 60° PHARMA ©2026 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. 21 ANALYSIS FRAMEWO
Slide 22: Tafenoquine Responses Exceeded Atovaquone Expectations
RELAPSING DISEASE Tafenoquine Responses Exceeded Atovaquone Expectations The comparison uses the duration of atovaquone actually coadministered with tafenoquine. 60 ° PHARMA ©2026 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. 22 Observed and expected 12 - week treatment - free r
Slide 23: Osakwe & Wormser: Brief Atovaquone, Long Tafenoquine
R E L A P SI N G D I SE A SE Osakwe & Wormser: Brief Atovaquone, Long Tafenoquine Two additional cures used a deliberate two-phase strategy. Two-phase regimen Only the first 10 days of tafenoquine were given with an atovaquone-containing combination; tafenoquine then continued alone for months. Pati
Slide 24: Expanded Access: Three Confirmed Cures; Two Outcomes Pending
R E L A P SI N G D I SE A SE Expanded Access: Three Confirmed Cures; Two Outcomes Pending A post-treatment NAT is used to test durable parasite clearance. CASE 1 NAT-negative Completed treatment and post-treatment NAT CASE 2 NAT-negative Completed treatment and post-treatment NAT CASE 3 NAT-negative
Slide 25: Randomized Hospital Study: Designed to Measure Faster Recovery
SE V E R E A C UT E D I SE A SE Randomized Hospital Study: Designed to Measure Faster Recovery The study remains blinded; no unblinded efficacy result is shown here. HOSPITALIZED PATIENTS N=30 2:1 randomization TAFENOQUINE + SOC 200 mg on Days 1–4, then 200 mg weekly for four weeks PLACEBO + SOC Mat
Slide 26: What the Interim Review Changed — and What It Did Not
SE V E R E A C UT E D I SE A SE What the Interim Review Changed — and What It Did Not The study remains blinded, but the operational decision is now clear. 1 DSMB interim review Reviewed the blinded program and recommended completing the originally planned study. 2 Safety acceptable No safety signal
Slide 27: Two Regulatory Paths After the Hospital Study Unblinds
R E G ULA T O R Y Two Regulatory Paths After the Hospital Study Unblinds The same evidence base supports either route; the randomized result determines the lead strategy. COMMON EVIDENCE BASE Marketed-drug safety • nonclinical combination activity • published cases • expanded-access outcomes • hospi
Slide 28: A CNPV Could Move a Potential Decision Into the 2027 Tick Season
R E G ULA T O R Y A CNPV Could Move a Potential Decision Into the 2027 Tick Season Illustrative timing — dependent on FDA alignment, dossier completeness and review needs. BASE PLAN CNPV PATH JAN 2027 Hospital unblinding LATE JAN / FEB Pre-sNDA meeting APR / MAY sNDA filing Q4 2027 Potential priorit
Slide 29: Clinicians: Help Define Pediatric Babesiosis Care
60° PHARMA ©2026 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved. 29 C O M M U N I T Y A C T I O N Clinicians: Help Define Pediatric Babesiosis Care Share your experience in a 10–15 minute survey focused on diagnosis, neuropsychiatric manifestations, treatment and unmet need. WHY Y
60 Degrees Pharmaceuticals — 2026 ILADS Annual Scientific Conference on 6ix